Taysha Gene Therapies to Release Full-Year 2020 Financial Results and Host Conference Call and Webcast on March 3

Rhea-AI Summary

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) announced it will report its financial results for the full year ended December 31, 2020, during a corporate update conference call on March 3, 2021, at 8:00 AM ET. The company focuses on developing AAV-based gene therapies for monogenic diseases of the central nervous system (CNS) and aims to translate treatments quickly from research to clinical applications. Taysha's collaboration with the UT Southwestern Gene Therapy Program enhances its pipeline targeting both rare and large patient populations.

Positive

• Developing AAV-based gene therapies targeting CNS monogenic diseases.
• Collaboration with UT Southwestern Gene Therapy Program strengthens development capabilities.
• Focus on both rare and large-market indications could enhance growth potential.

Negative

• None.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha”), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will report its financial results for full-year ended December 31, 2020, and host a corporate update conference call and webcast on Wednesday, March 3, 2021, at 8:00 AM Eastern Time.

Conference Call Details
Wednesday, March 3, at 8:00 AM Eastern Time / 7:00 AM Central Time
Toll Free:	833-614-1477
International:	914-987-7215
Conference ID:	3183829
Webcast:	https://ir.tayshagtx.com/news-events/events-presentations

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210301005234/en/

FAQ

When will Taysha Gene Therapies announce its financial results?

Taysha Gene Therapies will announce its financial results for the full year ended December 31, 2020, on March 3, 2021.

What is Taysha's focus in gene therapy?

Taysha focuses on developing AAV-based gene therapies for treating monogenic diseases of the central nervous system.

What time is Taysha's conference call on March 3, 2021?

The conference call is scheduled for 8:00 AM Eastern Time on March 3, 2021.

How can I access Taysha's conference call?

You can access Taysha's conference call by dialing 833-614-1477 (toll-free) or 914-987-7215 (international).

What types of diseases does Taysha Gene Therapies target?

Taysha targets monogenic diseases of the central nervous system, focusing on both rare and large patient populations.